Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Galapagos NV (GLPG : NSDQ)

• Company Description    Galapagos NV is a biotechnology company. The Company's operating segment consists of Research and Development and Services. Research and Development segment is engaged in the discovery and development of small molecules. Services segment offers drug discovery products and services. Its products include GLPG0634 for the treatment of rheumatoid arthritis and other inflammatory diseases, GLPG1205/GLPG1690 for treating inflammatory bowel disease, GSK2586184 for the treatment of chronic immuno-inflammatory diseases and GLPG0974, to prevent free fatty acid-induced activation and migration of neutrophils which are in different clinical trial. Galapagos NV is headquartered in Mechelen, Belgium. Number of Employees: 704

• Price / Volume Information    Yesterday's Closing Price: $30.30 Daily Weekly Monthly 20 Day Moving Average: 226,439 shares Shares Outstanding: (millions) Market Capitalization: $ (millions) Beta: 0.07 52 Week High: $31.23 52 Week Low: $22.36 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 4.95% 1.36% 12 Week 22.87% 3.69% Year To Date 10.18% 3.83%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL GEN DE WITTELAAN L11 A3 - MECHELEN,C9 2800 BEL ph: 321-534-2900 fax: 321-534-2901 ir@glpg.com http://www.glpg.com

• General Corporate Information    Officers Paul Stoffels - Chief Executive Officer and Chairman Thad Huston - Chief Operating Officer and Chief Financial Office Valeria Cnossen - Executive Vice President Annelies Missotten - Executive Vice President Michele Manto - Executive Committee Peer Information Galapagos NV (CORR.) Galapagos NV (RSPI) Galapagos NV (CGXP) Galapagos NV (BGEN) Galapagos NV (GTBP) Galapagos NV (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 36315X101 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 07/23/25 Share - Related Items Shares Outstanding: Most Recent Split Date: (:1) Beta: 0.07 Market Capitalization: $ (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.83 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.57 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 07/23/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.64 Price/Cash Flow: 41.73 Price / Sales: - EPS Growth vs. Year Ago Period: -733.33% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: 16.36% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - - 03/31/25 - - 12/31/24 - - Current Ratio 06/30/25 - - 03/31/25 - 7.95 12/31/24 - 9.97 Quick Ratio 06/30/25 - - 03/31/25 - 7.86 12/31/24 - 9.81 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - -1.12 Book Value 06/30/25 - - 03/31/25 - - 12/31/24 - 47.57 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - 0.53 Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©